IDT Australia Limited (ASX:IDT), a pharmaceutical manufacturing company based in Boronia, Victoria, has issued full-year guidance for FY27 forecasting revenue of $19 million to $20 million and EBITDA of $1.0 million to $1.5 million, compared to FY26 actual revenue of $16.8 million and EBITDA of negative $0.92 million.

Key Points

  • FY27 revenue guidance of $19M to $20M, representing growth of 13% to 19% over FY26 actual revenue of $16.8M
  • FY27 EBITDA guidance of $1.0M to $1.5M, an improvement of $1.9M to $2.4M over FY26 actual EBITDA of negative $0.92M
  • A new five-year contract secured with an existing radiopharmaceutical client, supported by the company's approximately $7 million facility upgrade program
  • IDT has disclosed a three-year target of $50 million in annual revenue, supported by expansion into new markets and deepening client relationships

FY27 Financial Guidance Details

According to the filing, IDT's FY27 guidance reflects a step-change in financial performance relative to FY26 actuals. Revenue from three verticals is forecast at $19 million to $20 million, against the FY26 actual of $16.8 million, representing growth of 13% to 19%. EBITDA is forecast at $1.0 million to $1.5 million, compared to negative $0.92 million in FY26, an improvement of $1.9 million to $2.4 million. The filing states that encouraging early benefits from the ongoing strategic reset program and committed key client contracts, which are expected to commence in the second half of FY27, underpin the guidance.

Strategic Reset and Customer Mix Shift

The filing states that following a strategic reset initiated early in FY26, IDT has focused on improving the quality and resilience of its revenue base. The company has prioritised engagement with larger and well-resourced pharmaceutical and biotech groups capable of supporting longer-term development and manufacturing programs. IDT said it is actively reducing revenue lumpiness inherent in the contract drug manufacturing sector by building a deeper backlog of projects across all three operating verticals. The filing notes that emerging biotech remains an important customer segment, but the change in customer mix is intended to better address revenue volatility.

Facility Upgrade and Radiopharmaceutical Contract

IDT disclosed an approximately $7 million investment to modernise its facilities and upgrade capabilities in both specialty orals and sterile manufacturing. The filing states this investment is one of the key reasons IDT was able to secure a further five-year contract with an existing radiopharmaceutical client. The filing also notes that a global pharmaceutical company has expressed interest in nurturing its existing relationship with IDT, potentially opening new opportunities beyond research and development work. IDT's Executive Chair, Mark Simari, stated the strategic reset is transforming IDT into a stronger, more focused organisation with improving earnings quality and a growing pipeline of potential work.